Mood drug inhibits breast cancer medication: study

Feb 08, 2010

A common antidepressant weakens or cancels the beneficial effects of a standard treatment for breast cancer, according to a study released Tuesday.

Women who take the mood drug paroxetine -- better known by its brand names Paxil and Seroxat -- at the same time as the breast cancer medication tamoxifen face an increased risk of death, researchers reported.

The antidepressant alone has no impact on the course of the disease but should not be taken at the same time as anti-cancer drug, the study recommended.

Tamoxifen significantly improves survival for the dominant type of breast cancer, the most commonly diagnosed cancer in women worldwide.

But to work properly, it must be converted by the liver into an active metabolite, the chemical that remains after a drug is broken down by the body.

It was previously suspected that antidepressants that boost the release of the naturally occurring neurotransmitter serotonin, such as paroxetine, might interfere with this process.

To find out, Catherine Kelly and colleagues at the Institute for Clinical Evaluative Sciences in Toronto, Canada investigated the health care records of 2,430 women with breast cancer who had received tamoxifen from 1993 to 2005.

About 30 percent of these women also received an antidepressant -- paroxetine more than any other -- at the same time, often prescribed over long periods to help patients cope with the stress of battling the deadly disease.

The use of paroxetine in combination with tamoxifen resulted in an increased long-term risk of breast cancer death -- approximately one additional fatality after five years of illness for every 20 women treated.

"These results highlight a drug interaction that is extremely common, widely underappreciated and potentially life-threatening, yet uniformly avoidable," said David Juurlink, a co-author or the study.

is prescribed to women who have so-called estrogen-receptor positive , which accounts for up to 80 percent of all cases of the disease.

Explore further: Prosocial internet support group not beneficial for breast cancer

add to favorites email to friend print save as pdf

Related Stories

Some antidepressants may risk breast cancer return

May 31, 2009

(AP) -- Breast cancer survivors risk having their disease come back if they use certain antidepressants while also taking the cancer prevention drug tamoxifen, worrisome new research shows.

Researchers: tamoxifen's power comes from endoxifen

Dec 11, 2008

Mayo Clinic researchers have discovered that a chemical known as endoxifen appears to be the primary metabolite responsible for the effectiveness of tamoxifen in treating breast cancer, and that it works against cancer in ...

Adding radiation decreases breast cancer recurrence

Jan 22, 2007

Radiotherapy after breast conserving surgery for breast cancer reduces recurrence and prevents development of additional breast tumors in older women with early stage breast disease, according to a new study. Published in ...

Recommended for you

Immune checkpoint inhibitors may work in brain cancers

Nov 21, 2014

New evidence that immune checkpoint inhibitors may work in glioblastoma and brain metastases was presented today by Dr Anna Sophie Berghoff at the ESMO Symposium on Immuno-Oncology 2014 in Geneva, Switzerland.

New model of follow up for breast cancer patients

Nov 21, 2014

Public health researchers from the University of Adelaide have evaluated international breast cancer guidelines, finding that there is potential to improve surveillance of breast cancer survivors from both a patient and health ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.